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ABSTRACT 
Author: Davidson, Rebecca. MS 
Institution: Purdue University 
Degree Received: August 2017 
Title: The Role of Stat3 in Skeletal Development. 
Major Professor: Jiliang Li 
Many factors are present in the development of skeletal tissue. Some factors lead to an 
increase in bone mass while some lead to a decrease. One factor that is known to have an 
influence on skeletal development is Signal Transducer and Activator of Transcription 3 
(Stat3). This knowledge arose because of a mutation in the Stat3 gene in humans causing 
a disease called Hyper-IgE Syndrome. This mutation leads to a variety of issues, 
including decreased bone mass. Because of this, our lab has sought to study Stat3 in its 
relation to bone. Many studies have already been conducted that discern how Stat3 
influences skeletal biology by observing its role in osteoclasts, osteoblasts, and other 
bone cells. Its role is still unclear, and many studies have provided seemingly 
contradictory results in how it works on bone tissue. Our lab set up several different 
studies in order to further elucidate what role Stat3 plays in skeletal development by 
looking at its effects on osteoblasts and osteoclasts, the bone-forming and bone-
destroying cells of the body, respectively. 
We conditionally knocked out Stat3 in the osteoblasts of mice and compared several 
different bone parameters to their wild type counterparts at 8 weeks of age. Differences 
were noted in bone phenotype, including decreased femur length, weight, bone mineral 
density, and bone mineral content in the cKO compared to their WT counterparts. While 
no significant difference in trabecular integrity was noted, several differences were 
observed in cortical bone. These differences indicate that Stat3 has a positive role in 
osteoblast differentiation, leading to an overall positive effect on bone mass. 
To observe the role of Stat3 in osteoclasts, in vitro experiments were set up in which pre-
osteoclast RAW 264.7 cells were manipulated with Stat3 siRNA or a Stat3 
overexpression construct and RANKL to induce differentiation. Using qPCR and western 
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blot assays, it was determined that when Stat3 is knocked down, several important genes 
in osteoclastogenesis and osteoclast function are more highly expressed than in the 
control groups. When Stat3 is overexpressed, a similar pattern is observed where these 
same genes are downregulated in the presence of higher Stat3 levels. These results 
indicate that Stat3 has an overall inhibitory effect on osteoclastogenesis and osteoclast 
function, indicating it has a positive effect on bone mass. 
Future studies could be performed to further elucidate the effects of Stat3 on skeletal 
development. Isolating the osteoblasts from cKO and WT mice and performing qPCR 
and western blot assays could be useful in finding out how Stat3 is influencing these cells. 
Further studies could also be done on the RAW 264.7 cells to find where Stat3 is 
interacting with the RANKL pathway. A resorption assay could be done with these cells 
to better understand how function might be influenced by Stat3. 
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 INTRODUCTION CHAPTER 1.
1.1 Bone Biology 
Bones serve many different purposes inside the body. They act as an anchor for muscles 
to support movement as well as a shield for the most delicate of internal organs (Clarke). 
Bones provide mechanical strength and are necessary for load bearing (Burr and Ozan). 
They aid the body in mineral homeostasis by providing storage for ions such as calcium 
that can be released when needed for different cellular pathways and muscle contraction 
(Burr and Ozan). They are also the site of hematopoiesis and play an important role in 
endocrine function (Burr and Ozan). Bone is clearly an exceptionally important organ, 
however unobvious this fact may be at first glance. Knowing what bones consist of and 
how they are created on a cellular and molecular level can aid in the discovery of new 
medications and therapies that seek to treat bone diseases such as osteoporosis and 
osteopenia. 
1.2 Skeletal Macrostructure 
The vertebrate skeleton is divided into two parts: the axial skeleton and the appendicular 
skeleton (Solomon, Berg and Martin). Within the appendicular skeleton are the bones of 
the upper and lower extremities, many of which are long bones (Solomon, Berg and 
Martin). These bones are made up of a long shaft called the diaphysis, and two ends 
referred to as the epiphyses (Solomon, Berg and Martin). The metaphysis is an area of 
growth between the diaphysis and epiphysis that exists in youth, but disappears in later 
development (Solomon, Berg and Martin). A sheath of connective tissue called the 
periosteum surrounds the long bone, and the endosteum surrounds a hollow cavity within 
the bone which houses the bone marrow (Solomon, Berg and Martin). The diaphysis in 
the long and short bones of the skeleton is made up primarily of cortical bone, which is 
relatively dense and compact (Burr and Ozan). This type of bone contains Haversian 
canals that offer some porosity to its otherwise solid structure (Burr and Ozan). However, 
cortical bone is still sturdy and strong, which allows for structural support and protection 
(Burr and Ozan). The metaphyses in the long bones of the skeleton are made up primarily 
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of cancellous bone, which is much more porous than cortical bone (Burr and Ozan). 
Sometimes referred to as spongy or trabecular bone, cancellous bone is mainly composed 
of long rods, or trabeculae, connected to each other in a meshwork that allow for 
mechanical strength (Burr and Ozan). Within this meshwork is a hollow space for bone 
marrow to reside (Burr and Ozan). 
1.3 Skeletal Microstructure 
A large portion of the bone is made up of lamellae, which are concentric circles 
comprised of mineral and collagen (Burr and Ozan). These lamellae can be found around 
the periosteum and endosteum and within trabeculae (Burr and Ozan). Unlike lamellar 
bone, woven bone is not well organized due to rapid formation rate (Burr and Ozan). 
Woven bone is laid down quickly, typically due to an urgent need for new bone as in 
times of damage or great mechanical stress (Burr and Ozan). During woven bone 
formation, collagen fibers are rapidly deposited and mineralized (Burr and Ozan). Unlike 
woven bone which can be deposited without any pre-existing surface, primary bone must 
be deposited onto cartilage or bone that has already been formed (Burr and Ozan). There 
are three different types of primary bone: primary lamellar bone, plexiform bone, and 
primary osteons (Burr and Ozan). All of these types of primary bone differ in how they 
are organized and what their function is (Burr and Ozan). Primary lamellar bone is 
deposited in dense lamellar sheets, which provide strength to periosteal, endosteal, and 
trabecular surfaces (Burr and Ozan). Plexiform bone is used for rapid growth (Burr and 
Ozan). The non-lamellar portion is deposited de novo and primary lamellar bone is 
deposited on the surface (Burr and Ozan). Lastly, primary osteons form on the surface of 
large vascular canals, essentially decreasing the diameter of these canals by adding 
several osteonal layers on the inside (Burr and Ozan). Secondary bone is another bone 
type that differs from primary bone in that it uses highly coordinated coupling of 
resorption and formation on a pre-existing bone surface (Burr and Ozan). Interstitial bone 
is the type of bone that is left untouched during the remodeling process (Burr and Ozan). 
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1.4 Bone Composition 
The three main components of bone are water, organic material, and mineral (Burr and 
Ozan). The main mineral found in bone is carbonated apatite, and the organic material 
consists mostly of type I collagen, as well as NCPs (noncollagenous proteins) that are 
mainly extracellular but also exist within the bone cell (Burr and Ozan). Among these 
noncollagenous proteins are proteoglycans, glycosaminoglycans, glycoproteins, and other 
proteins such as osteocalcin and osteonectin (Burr and Ozan). These noncollagenous 
proteins are important in roles such as controlling mineral deposition (Burr and Ozan). 
Collagen plays an important role in the bone of retaining flexibility and suppleness, while 
the main role of mineral is to provide rigidity (Burr and Ozan). Water is also an important 
component of the bone because without it, the bone will become too stiff and can break 
more easily (Burr and Ozan). The way in that the collagen and mineral are deposited 
dictates what type of function they might have and what the newly forming bone can be 
used for (Burr and Ozan). If the bone forms rapidly in a more unorganized fashion, this 
could mean the bone was needed for a quick repair (Burr and Ozan). However, if the 
bone deposits more slowly and carefully, this could mean the bone was needed in 
response to mechanical loading that created microfractures (Burr and Ozan). 
1.5 Bone Cells 
1.5.1 Osteoclasts 
Within the bone, there are several different cell types. One of these types of cells is 
osteoclasts, which are responsible for breaking bone down (Bellido, Plotkin and 
Bruzzaniti). Osteoclasts are derived from the hematopoietic cell progenitor line that also 
gives rise to macrophages and monocytes (Z. Zhang et al.). Which type of cell the 
progenitor becomes is dependent on which factors are present in the environment, 
essentially dictating what type of stimulation they will receive to differentiate. 
Osteoclasts are stimulated by Receptor Activator of Nuclear factor Kappa-B Ligand 
(RANKL), a member of the Tumor Necrosis Factor (TNF) ligand family, which activates 
a pathway leading to the release of several different factors that cause bone to break 
down (Bellido, Plotkin and Bruzzaniti). Upon RANKL binding to Receptor Activator of 
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Nuclear factor Kappa-B (RANK) on the osteoclast surface, TNF receptor-associated 
factor 6 (TRAF6) is activated, causing a cascade that ultimately induces osteoclast 
differentiation, also referred to as osteoclastogenesis (Bellido, Plotkin and Bruzzaniti). 
Nuclear factor-kappa B (Nfkb) is a highly important factor in this cascade, causing the 
upregulation of c-Fos which, in turn, upregulates nuclear factor of activated T-cells 1 
(NFATc1) (Bellido, Plotkin and Bruzzaniti). (Figure 1) NFATc1 is critical for 
differentiation of osteoclasts and remains an intensely studied transcription factor in 
osteoclastogenesis. 
When bone needs to be broken down, osteoclast precursors arrive at the bone surface, 
proliferate, differentiate, and fuse into multi-nucleated osteoclasts (Bellido, Plotkin and 
Bruzzaniti). Osteoclast precursors are recruited to the site by several factors which 
include calcium gradients and osteoblast-mediated signaling (Bellido, Plotkin and 
Bruzzaniti). Once they arrive at the bone surface, several growth factors come into play 
to cause them to proliferate into committed mono-nucleated pre-osteoclasts (Bellido, 
Plotkin and Bruzzaniti). They then differentiate in response to RANKL expressed on the 
surface of osteoblasts and osteocytes (Bellido, Plotkin and Bruzzaniti). RANKL and 
several other factors, including V-ATPase subunit D2, also assist in osteoclast fusion to 
form multinucleated cells (Bellido, Plotkin and Bruzzaniti). 
Once the osteoclast has fused, it attaches itself to the bone surface where polarization of 
the cell occurs (Bellido, Plotkin and Bruzzaniti). The area of the cell on the bone surface 
is the apical side, where the factors needed to break the bone down are secreted (Bellido, 
Plotkin and Bruzzaniti). Direct contact of the cell to the bone surface is made through an 
area known as the sealing zone where podosomes consisting of filamentous actin on the 
apical surface of the osteoclast touch the bone surface (Bellido, Plotkin and Bruzzaniti). 
Inward of the sealing zone is a transition zone to the ruffled border (Bellido, Plotkin and 
Bruzzaniti). There is a gap of space in between the ruffled border and bone surface where 
factors are secreted that result in bone dissolution (Bellido, Plotkin and Bruzzaniti). 
In order to begin tearing up the unwanted areas of bone, the osteoclast releases several 
factors onto the bone surface. Carbonic anhydrases create protons which vacuolar 
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ATPases then release into the environment between the osteoclast and the bone surface, 
causing it to become acidic (Bellido, Plotkin and Bruzzaniti). Cathepsin K is also 
released, which is a protease that eats away at the collagenous bone matrix (Bellido, 
Plotkin and Bruzzaniti). The degraded material is engulfed inside the osteoclast by 
vacuoles that move to lysosomes, bringing the broken-down bone material into the cell to 
be further processed and used for other cellular processes (Bellido, Plotkin and 
Bruzzaniti). 
At the conclusion of the bone resorption event, osteoclast apoptosis occurs (Bellido, 
Plotkin and Bruzzaniti). This process is currently not well understood. However, there are 
several factors that likely lead to osteoclast cell death. Calcium that is released by the 
degraded bone material potentially helps trigger this event, as well as Fas ligand secreted 
by osteoblasts and integrin signaling (Bellido, Plotkin and Bruzzaniti). The down-
regulation of anti-apoptotic factors such as RANKL and M-CSF could also contribute to 
this programmed cell-death (Bellido, Plotkin and Bruzzaniti). 
1.5.2 Osteoblasts 
Another type of bone cell is osteoblasts, which are needed to form new bone (Bellido, 
Plotkin and Bruzzaniti). These cells are derived from the mesenchymal stem cell lineage 
that also gives rise to chondrocytes and adipocytes (Fakhry et al.). Mesenchymal stem 
cells receive signals from proteins such as Wnts, bone morphogenic protein (BMP)-2, 
and parathyroid hormone (PTH) to induce differentiation into the osteoblast lineage 
(Kapinas et al.). (Figure 2) Wnts play a role in several different time points throughout 
the differentiation process (Kapinas et al.). They help MSCs proliferate, aid in 
committing the cells to being osteo-chondro precursors, and work to prevent osteoblast 
apoptosis (Bellido, Plotkin and Bruzzaniti; Kapinas et al.). The osteo-chondro precursers 
are then induced by factors such as Runx2 in order to become preosteoblasts (Bellido, 
Plotkin and Bruzzaniti). Further induction occurs into immature osteoblasts, followed by 
their final form as mature osteoblast cells (Bellido, Plotkin and Bruzzaniti). Once these 
mature osteoblasts have finished forming new bone matrix, they either undergo apoptosis, 
differentiate further into osteocytes that embed into the newly formed bone, or remain on 
the inactive bone surface as lining cells (Bellido, Plotkin and Bruzzaniti). 
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Osteoblast progenitors proliferate and are maintained by several transcription factors 
prior to differentiation (Bellido, Plotkin and Bruzzaniti). Runx2 and Osterix are two 
crucial transcription factors in osteoblastogenesis that are controlled by a variety of 
extracellular ligands such as the WNTs, BMPs, and FGFs, and are needed in order to 
activate several genes involved in bone formation (Bellido, Plotkin and Bruzzaniti; Y. 
Zhang et al.). After osteoblasts proliferate, they begin depositing bone matrix proteins 
such as type I collagen and mineralizing this bone to form osteoid (Bellido, Plotkin and 
Bruzzaniti). This is most often followed by cell death (Bellido, Plotkin and Bruzzaniti). 
Each of these stages is distinct in that different genes are turned on and different markers 
are expressed (Bellido, Plotkin and Bruzzaniti). 
1.5.3 Other Bone Cells 
Aside from osteoblasts and osteoclasts, there are several other bone cells that play critical 
roles in maintaining bone homeostasis. One such cell is the osteocyte, discussed 
previously. This cell type forms from osteoblasts that have become encased within newly 
formed bone (Bellido, Plotkin and Bruzzaniti). This encasement is likely a deliberate 
process that keeps the osteocytes in an ideal position within lacuna in the newly formed 
matrix (Dallas, Prideaux and Bonewald). They are important for mediating signals 
between other bone cells and sensing when stress has been put on different areas of the 
bone. While these mechanisms are still not well-understood, it has been proposed that 
osteocytes sense this strain through the cell body, glycocalyces on dentritic processes, 
and/or cilia bending (Bonewald). The dendrites move through canaliculi in order to make 
contact with bone cells and the vasculature woven through the matrix (Dallas, Prideaux 
and Bonewald). They are able to contact and communicate with other cells that have 
connexin43 (Cx43) gap junctions (Buo and Stains). 
Monocytes and macrophages have also been shown to have an important role in 
osteoblast differentiation by producing oncostatin M (OSM) which leads to a signaling 
cascade that causes osteoblasts to differentiate from mesenchymal stem cells (MSCs) 
(Nicolaidou et al.). 
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1.6 Signaling Among Bone Cells 
When mechanical strain is placed on the bone, or there is not enough strain on the bone to 
justify its current mass, different signals must be sent out in order to recruit the proper 
cells to the site that can fix the issue. Bone marrow stromal cells (BMSCs), osteoblasts, 
and osteocytes all express M-CSF and RANKL, which are essential for osteoclast 
differentiation (Bellido, Plotkin and Bruzzaniti). Additionally, osteoblasts and osteocytes 
secrete osteoprotegerin (OPG) which can bind RANKL, preventing its induction of the 
cellular pathway that leads to osteoclastogenesis (Bellido, Plotkin and Bruzzaniti). OPG 
essentially negatively regulates osteoclastogenesis and an imbalance of OPG in relation 
to RANKL can cause issues that lead to osteoporotic or osteopetrotic phenotypes 
(Teitelbaum). 
1.7 Skeletal Development 
1.7.1 Endochondral Bone Development 
There are two main types of bone development: endochondral and intramembranous 
(Solomon, Berg and Martin). Endochondral bone development occurs mainly in the long 
bones (Solomon, Berg and Martin). This kind of bone development creates a 
cartilaginous template that can later be ossified (Solomon, Berg and Martin) 
Endochondral ossification begins with a cluster of mesenchymal stem cells differentiating 
into chondroblasts with the help of transcription factor SOX-9 (Allen and Burr) These 
chondroblasts produce a cartilaginous matrix that resembles the final bone shape (Allen 
and Burr) Chondroblasts that embed within the cartilage become chondrocytes, and the 
cartilage itself becomes surrounded by a perichondrium (Allen and Burr) This 
perichondrium contains cells that differentiate into osteoblasts via transcription factor 
RUNX2, and deposit bone matrix onto the cartilage template (Allen and Burr) This newly 
forming lamellar bone takes over around the diaphysis, turning the perichondrium into 
periosteum (Allen and Burr). As the area becomes vascularized, a primary ossification 
center appears that will continue to aid the development of the bone (Allen and Burr). A 
secondary ossification center also appears in the epiphysis (Allen and Burr). The junction 
between the diaphysis and epiphysis, referred to as the epiphyseal or growth plate, 
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contains different regions of cells that aid in longitudinal growth (Allen and Burr). There 
are five different zones of cells in this area from the furthest to the primary ossification 
center to the nearest: the resting zone, the proliferative zone, the hypertrophic zone, the 
calcified cartilage zone, and the zone of ossification (Allen and Burr). During this process, 
osteoclast precursors are recruited to the mesenchyme surrounding the bone where they 
proliferate and differentiate before moving through the bone collar and hollowing out the 
marrow cavity within the developing long bone (Engsig et al.). 
1.7.2 Intramembranous Bone Development 
Intramembranous ossification occurs in the bones of the skull as well as the clavicles 
(Allen and Burr). This type of bone formation occurs mainly through the use of 
mesenchymal stem cells that, through expression of RUNX2, are driven directly into 
differentiating into osteoblasts (Allen and Burr). These osteoblasts then rapidly form 
woven bone that they later can add more woven bone or primary lamellar bone onto 
(Allen and Burr). 
1.8 Bone Modeling and Remodeling 
1.8.1 Bone Modeling 
Bone modeling occurs during skeletal development when bone is being either formed by 
osteoblasts or resorbed by osteoclasts on a pre-existing surface (Solomon, Berg and 
Martin). Formation modeling occurs when osteoblasts are recruited to the site, while 
resorptive modeling occurs when osteoclasts are recruited to the site (Allen and Burr). 
Modeling will occur when either cell is activated and used to either resorb or form bone 
(Allen and Burr). Either type of modeling can occur on either trabecular, endosteal, or 
periosteal surfaces (Allen and Burr). Formation modeling will occur when a certain level 
of strain has occurred in a certain area of the bone, while resorptive modeling will occur 
when too low an amount of strain has been placed on the bone (Allen and Burr). This 
ensures that there is always an appropriate amount of bone relative to the strain being 
placed on the bone. Forming new bone is expensive, so only performing formation 
modeling when there is too much strain is essential. Bone also contains precious 
materials such as calcium that the body could use for other important processes if the 
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bone does not need as much strength in that area. Modeling involves both an activation 
stage and a formation or resorption phase (Allen and Burr). Depending on the level of 
strain occurring in the surrounding tissue, the activation stage will involve the 
recruitment of precursors that will either differentiate into osteoblasts or osteoclasts, and 
the bone will either be formed or resorbed respectively (Allen and Burr). Lining cells 
already on the bone surface can also be called upon to differentiate back into mature 
osteoblasts and deposit new bone matrix (Allen and Burr). In bone modeling, formation 
and resorption occur on different surfaces of the bone, often in order to support radial 
growth or shift the cortex from the central axis (Allen and Burr). Essentially, bone will be 
resorbed on the endosteal surface and formed on the periosteal surface (Allen and Burr). 
1.8.2 Bone Remodeling 
Remodeling occurs during the adult lifespan when old bone needs to be removed and 
replaced with new bone (Solomon, Berg and Martin). Both osteoblasts and osteoclasts 
play a role in this process (Solomon, Berg and Martin). Unlike in bone modeling, 
resorption and formation occur sequentially when the bone is being remodeled (Solomon, 
Berg and Martin). In remodeling, the mechanism is activation followed by resorption 
followed by formation (Allen and Burr). Essentially, osteoclasts begin the process by 
initiating the resorption event, a transition occurs moving from resorption to formation, 
and osteoblasts finish the process by forming the new bone (Florencio-Silva et al.). The 
coordination between osteoclasts and osteoblasts in this process must be finely tuned to 
maintain the proper structure of the bone surface being remodeled (Andersen et al.). Once 
osteoclasts have finished resorbing the damaged bone, they recruit osteoblasts both 
indirectly via the release of growth factors from the broken-down bone matrix as well as 
directly through making contact with these osteoblasts and releasing certain secreted 
factors (Khosla, Oursler and Monroe). 
1.9 STAT Overview 
Signal Transduction and Activation of Transcription (STAT) family transcription factors 
are activated by Janus Kinase 2 (JAK2) and mediate cell survival, differentiation, and 
proliferation (Lodish et al.; Zhou et al.). There are seven different STAT proteins in 
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mammals: STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6 
(Timofeeva et al.). Each of these proteins consists of an N-terminal domain with 
oligomerization and coiled-coil domains, a DNA binding domain (DBD), a linker domain, 
a Src homology 2 (SH2) domain, and a C-terminal transactivation domain on which 
phosphorylation can occur (Lodish et al.; Timofeeva et al.; Fagard et al.). 
Different cytokines and growth factors can activate different receptors on the cell surface 
that induce different signals through the cell (Lodish et al.). These receptors are attached 
to a JAK2 kinase on the cytosolic side of the membrane that can phosphorylate STAT 
transcription factors within the cell (Lodish et al.). 
1.10 STAT Activation 
Activation of STAT begins with a cytokine or growth factor binding to a receptor (Lodish 
et al.). These receptors for STAT activation have an extracellular domain where the 
cytokine or growth factor can bind, and an intracellular domain associated with JAK 
kinases (Lodish et al.). JAK proteins can associate with GPCRs, LIF-Rs, IL-Rs, and 
gp130 (Carpenter and Lo). Upon ligand binding, a conformation change occurs in the 
receptor, causing the JAK kinase domains to come together and phosphorylate each other 
on a specific tyrosine on the activation lip (Lodish et al.). The activation lips move away 
from the active site and the JAK proteins phosphorylate several tyrosines on the cytosolic 
end of the cytokine receptor (Lodish et al.). These phosphotyrosines act as docking sites 
for SH2 domains to bind (Lodish et al.). Since STAT proteins contain an SH2 domain, 
they are able to bind the docking site and become phosphorylated by JAK on the C-
terminal domain on Y705/S727 (Lodish et al.; Xu et al.). Phosphorylation of STAT 
causes its dissociation from the receptor and dimerization with another STAT protein 
(Lodish et al.). The SH2 domain of either STAT associates with the phosphotyrosine on 
the other STAT (Lodish et al.). The proteins can either form a homodimer with the same 
kind of STAT protein or a heterodimer with a different kind of STAT protein (Delgoffe 
and Vignali). The Nuclear Localization Sequence (NLS) sites within the coiled-coil and 
dimer-dependent DNA-binding domains on the STAT dimer are exposed in this 
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conformation, allowing the dimer to easily move into the nucleus and bind the enhancer 
on a DNA molecule (Lodish et al.; Fagard et al.). 
1.11 STAT Transcription 
The DBD of the STAT homodimer either binds interferon gamma-activated sequence 
(GAS) or serum-induced element (SIE) which both reside in the promoter region of the 
desired target gene (Timofeeva et al.; Xu et al.). One SIE that STAT can bind lies in the 
promoter region of cellular (c)-Fos (Cressman, Diamond and Taub). Other promoters that 
specific STAT proteins can bind include p53, MMP-9, and IL-6 (Carpenter and Lo). 
1.12 STAT Regulation 
There are several methods the cell can use to regulate the JAK/STAT pathway. One 
method, used for short-term regulation, is through the activation of SHP1 (Lodish et al.). 
This phosphotyrosine phosphatase has an SH2 domain that binds a phosphotyrosine on a 
cytokine receptor, revealing another active site on the protein (Lodish et al.). This active 
site can essentially pull off the phosphate group on the JAK kinase, causing its 
inactivation (Lodish et al.). 
Another method, used for long-term regulation, is through the recruitment of the SOCS 
protein (Lodish et al.). SOCS is activated by the JAK/STAT signaling pathway, creating 
a negative feedback loop (Lodish et al.). SOCS has an SH2 domain that can bind 
phosphotyrosines on the cytokine receptor, as well as the phosphotyrosine on the 
activation lip of JAK (Lodish et al.). This prevents STATs from binding the receptor and 
JAKs from phosphorylating STAT (Lodish et al.). SOCS proteins also have a SOCS box 
that can recruit E3 ubiquitin ligase, which can ubiquitinate JAK2 upon binding causing 
its degradation within a proteasome (Lodish et al.). 
Protein inhibitor of activated STAT (PIAS) is another common regulator of STAT 
signaling (Heinrich et al.). PIAS acts by binding a STAT protein after it has been 
phosphorylated on Tyr 727 (Heinrich et al.). The exact mechanism of PIAS function on 
STAT is unclear (Heinrich et al.). However, PIAS has been known to demonstrate E3-
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Small Ubiquitin-Like Modifier (SUMO) ligase activity, which could help relocate the 
STAT protein to another area of the nucleus to become inactive (Heinrich et al.). 
1.13 Stat3 
Stat3 is a member of the STAT family of transcription factors. This particular STAT 
protein was discovered in 1994 (Mogensen). This protein is 770 amino acids in length 
and the gene encoding this molecule can be found on chromosome 17q21 (Mogensen). 
Like other members of the STAT family, Stat3 has an N-terminal domain (1-130), a 
coiled-coil domain (130-320), a DNA binding domain (DBD, 320-465), a linker domain 
(465-585), an SH2 domain (585-688), and a C-terminal transactivation domain (688-
770)(Holland et al.; Fagard et al.; Xu et al.). (Figure 3) Descriptions based on the 
structure of the protein list an N-terminal region (1-355) which includes the N-terminal 
domain and a portion of the DBD, a central area (355-555) with the other portion of the 
DBD, and a C-terminal domain (555-770) which includes the SH2 domain (Xu et al.). 
Stat3 activation can occur through a variety of cytokines and growth factors, including 
Interleukin (IL)-6 (Mogensen). (Figure 4) Stat3 has been shown to activate upon 
phosphorylation by Tyrosine Kinase (Tyk) 2, Jak1, Jak2, and Jak3 based on what 
ligand/receptor combination is used (Rebe et al.). Dimerization occurs once the K685 is 
acetylated and the Y705/S727 is phosphorylated (Xu et al.). Upon activation and 
dimerization, Stat3 most often forms a homodimer but can also form a heterodimer with 
Stat1 or Stat5 (Mogensen). Stat3 then undergoes further modification through 
phosphorylation of Tyr 727, acetylation, and methylation (Mogensen). Stat3 then can 
enter the nucleus and bind promoters for genes such as Socs3, Fosl1, Jun, and Jak2 
(Dauer et al.). Several residues in the DBD - E434, E435, V461, V462, V463 – are 
needed in order to bind the SIE in the promoter sequence (Xu et al.). Once Stat3 has 
successfully induced its target genes, it is dephosphorylated and sent back into the 
cytoplasm to be recycled (Mogensen). 
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1.14 Stat3 in Hyper-IgE Syndrome (HIES) 
1.14.1 HIES Characterization 
Hyper-immunoglobulin E syndrome (HIES) is a disorder commonly associated with 
Stat3. There are two different types of HIES, Type 1 and Type 2 (Minegishi and 
Karasuyama). Type 1 is caused by mutations in Stat3 whilst Type 2 is characterized by a 
null mutation in Tyk2 (Minegishi and Karasuyama). Both types have similar issues in 
that cytokine signaling is significantly impaired, leading to many problems with the 
immune system – particularly from T-helper type 17 cells – and several other cellular 
functions (Minegishi and Karasuyama). Type 1 HIES, more commonly referred to as 
autosomal dominant hyper-immunoglobulin E syndrome (AD-HIES), or Job’s Syndrome, 
is a disorder in which there is an autosomal dominant mutation of the Stat3 gene in 
humans. Patients with AD-HIES have several major issues including elevated IgE levels, 
connective tissue abnormalities, and skeletal development abnormalities (Sowerwine et 
al.). Some studies have shown that many patients with AD-HIES have osteopenic or 
osteoporotic phenotypes (Sowerwine et al.). There is evidence these phenotypes occur 
due to an increase in osteoclast activity (Sowerwine et al.). Stat3 is activated in the 
presence of factors such as IL-6, IL-10, IL-11, IL-17, IL-21, and IL-22, so when Stat3 is 
not functioning correctly, all of these cellular pathways are negatively affected 
(Mogensen). The wide range of issues caused by Stat3 mutations demonstrates the 
breadth of Stat3’s effect on different cell types. Stat3 clearly has an important role to play 
in many tissues of the body, including bone. 
1.14.2 HIES Mutations 
When the link between AD-HIES and Stat3 was made, mutations were found at several 
different amino acids including R382, F384, R423, and V463 in the DBD and V637 in 
the SH2 domain (Holland et al.). Each of these amino acid changes has multiple 
mutations that can occur that influence them (Holland et al.). These mutations in Stat3 
can either be missense or in-frame deletions, and they do primarily occur in the DBD and 
SH2 domains (Mogensen). They have occasionally been shown to occur in the 
transactivation domain as well (Giacomelli et al.). The mutations that occur within the 
DBD prevents binding to the promoter regions of the target genes Stat3 affects through 
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SIE, which impairs the transcription of several critical factors (Xu et al.). These 
mutations have the potential to cause changes in several different amino acids including 
R382Q, R382W or V463Δ which are critical for DBD binding to the promoter sequence 
(Xu et al.). SH2 mutations inhibit the initial activation step where Stat3 needs to bind to 
the receptor in order to be phosphorylated by the Jak protein (Giacomelli et al.). Some 
amino acid changes caused by these mutations are V637M and M660R (Giacomelli et al.). 
1.15 Stat3 Effect on Bone 
Many studies have been done that demonstrate that Stat3 has an effect on bone 
morphology and development. The extent of this effect and whether the effect is positive 
or negative is still unclear. Many studies show what appear to be conflicting results in 
this respect. HIES patients have a mutation in Stat3 that typically causes a net loss in 
bone mass, which might indicate that Stat3 has an overall positive effect on bone mass 
essentially preventing bone from being broken down too much. However, the answer 
might not be as simple as this. There are several researchers who have studied and are 
currently studying different ways Stat3 could affect bone mass. 
One study that also used an in vivo system incorporated an α1(I)-collagen Cre-LoxP to 
conditionally knock out Stat3 in osteoblasts (Itoh et al.). They found that transgenic mice 
tended to have osteoporotic phenotypes, suggesting the osteoblast function was impaired 
when Stat3 was deficient in osteoblasts (Itoh et al.). The main conclusion is that Stat3 
positively regulates osteoblast differentiation to support bone formation, similar to our 
findings (Itoh et al.). 
Another study confirmed the involvement of Stat3 in osteoblast differentiation by 
transfecting cells with either constitutively active or dominant negative Stat3 (Nicolaidou 
et al.). demonstrated that Stat3 is essential for causing osteoblast differentiation from 
mesenchymal stem cells (Nicolaidou et al.). This was an in vitro study, so they were 
unable to assess how osteoblast activity was affected in any way. However, this study 
demonstrated the vital role Stat3 plays in causing osteoblasts to differentiate from 
mesenchymal stem cells. Stat3 studies in relation to osteoblasts seem to be in agreement 
that Stat3 has a positive effect on osteoblasts, be it by assisting in their commitment, 
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differentiation, or function. There is currently not much information available on the 
extent of this effect and how bone mass is affected by it. 
One lab did study the effect of Stat3 on osteoclasts in vivo and in vitro (Z. Zhang et al.). 
They began by conditionally knocking out Stat3 in hematopoietic stem cells (HSCs) of 3-
4 week old mice using Tie2-Cre, which likely did not affect osteoblast cells but affected 
osteoclasts (Z. Zhang et al.). This Cre is not specific for osteoclasts, so may have also 
knocked Stat3 out in other cell types produced from HSCs. From this experiment, they 
found increased osteoporosis based on decreased trabecular/cortical bone mass that was 
likely caused by increased osteoclast precursor/osteoclast number (Z. Zhang et al.). Cells 
from these mice were cultured in vitro for further testing (Z. Zhang et al.). They analyzed 
c-Fos mRNA and protein levels in osteoclast precursor cells and showed these levels 
greatly increase in the absence of Stat3 (Z. Zhang et al.). One conclusion of this study is 
that because c-Fos is needed for osteoclast differentiation, Stat3 is a negative regulator of 
osteoclastogenesis due to its apparent inhibitory effect on c-Fos (Z. Zhang et al.). 
Another study was done to elucidate the role of Stat3 in osteoclastogenesis using a 
similar model to ours. The researchers in this study cultured mouse osteoclast precursor 
RAW264.7 cells with M-CSF, RANKL, and varying concentrations of JAK inhibitor 
AG490 (Li et al.). They found that the addition of AG490 inhibited osteoclast formation 
compared to cells without (Li et al.).  When they added only RANKL with AG490, they 
saw a decrease in cell surface receptor RANK (Li et al.). The general conclusion of this 
paper is that AG490 inhibits osteoclastogenesis (Li et al.). From this, they believe that 
Stat3 must be a positive regulator of osteoclastogenesis (Li et al.). They also saw that 
adding AG490 to RAW264.7 cells with or without RANKL inhibited cell growth and 
proliferation, indicating Stat3 could be important for maintaining the cell population (Li 
et al.). One issue with this study is that JAK inhibition is not simply Stat3 inhibition. JAK 
is influenced by many different cytokines and growth factors and affects many different 
cellular pathways that do not directly involve Stat3. The experimental design used in this 
paper does not have the same level of clinical relevance to HIES as studies that directly 
use Stat3 as their target. This study did demonstrate that because AG490 inhibits RANKL 
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effects, JAK must be downstream of RANKL (Li et al.). Essentially, AG490 inhibits 
RANKL-induced activation of Stat3 (Li et al.). 
A study that used human embryonic kidney HEK293 cells, interestingly enough, shed 
some light on whether Stat3 could have a positive or negative effect on 
osteoclastogenesis (Wei et al.). Their focus was on the interaction of TRAF6, an 
important protein activated by RANKL signaling, and Stat3 (Wei et al.). When they used 
an antibody to precipitate Stat3, they found that TRAF6 co-precipitated, demonstrating 
the two proteins interact (Wei et al.). Through further analysis, they were able to 
demonstrate that TRAF6 interacts with Stat3 to ubiquitinate this protein as a target for 
destruction (Wei et al.). One could speculate that because TRAF6 is needed to induce 
osteoclastogenesis and it inhibits Stat3, the latter could be important in down-regulating 
osteoclastogenesis.  
1.16 Research Goals 
Currently, there is research that promotes the idea Stat3 has an effect on bone 
development and morphology. Some of the research seems to be contradictory in that 
there is not a consensus on whether Stat3 has a positive or negative effect on bone 
development. Currently, most researchers seem to agree that Stat3 has an inhibitory effect 
on osteoclastogenesis and osteoclast function and a promotional effect on 
osteoblastogenesis and osteoblast function, but the mechanisms are still not well 
understood. Many researchers have even suggested that Stat3 has a positive role in 
osteoclastogenesis, causing an overall catabolic effect on the skeleton. 
Our lab created Stat3 conditional knockout mice in the osteoblasts of developing mice 
with an Osterix promoter to further explore the role of Stat3 in osteoblasts. Osterix is an 
important protein that assists in differentiating a pre-osteoblast to a fully functional 
osteoblast. Because of this, the Osterix promoter was used specifically to knock out Stat3 
in pre-osteoblasts in an effort to understand how osteoblasts are affected by Stat3 
deletion. We hypothesize that when Stat3 is not present in fully developed osteoblasts, 
there are deficits in the developing skeleton. 
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Stat3 was also knocked down in pre-osteoclasts specifically to understand how osteoclast 
differentiation and function are affected by a deficiency of Stat3. To test how 
differentiation and function might be affected, RANKL was added to a control and a 
Stat3 knockdown group. RANKL is used to differentiate osteoclasts, so this would cause 
an upregulation in genes important in osteoclastogenesis and osteoclast function. If Stat3 
affected these genes, an upregulation or downregulation of said genes would be 
visualized upon siRNA knockdown. For similar reasons, Stat3 overexpression was 
performed to test if a similar pattern would be seen as with siRNA knockdown. For 
instance, if a gene was upregulated when Stat3 was knocked down, the same gene should 
have been downregulated when Stat3 was overexpressed. Genes that are known to be 
important in differentiation and function were chosen in order to test how important Stat3 
is in bone resorption. Our findings show that Stat3 downregulates genes important for 
osteoclast differentiation and function, resulting in a positive effect on bone mass. Our 
hypothesis is that Stat3 does have a negative effect on osteoclastogenesis and a positive 
effect on osteoblastogenesis, thus providing an overall anabolic effect on skeletal 
development. The goal of this study is to test this hypothesis by elucidating what roles 
Stat3 has on bone development based on how it affects osteoclasts in vivo using a cKO 
system and in vitro by using siRNA knockdown and an overexpression construct of Stat3, 
and how it affects osteoblasts in vivo using a cKO system in early osteoblast 
differentiation.   
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 MATERIALS AND METHODS CHAPTER 2.
2.1 In vivo Mouse Study 
2.1.1 Experimental Mice 
In order to knock out Stat3 in osteoblasts of experimental mice, a cre-loxP recombinase 
system was used. The Osterix promoter was used ensuring Stat3 was only knocked out in 
early osteoblasts. LoxP flanked the 18-20 exons on the Stat3 gene that are responsible for 
encoding the SH2 region, which is needed for activation. 
2.1.2 Breeding Scheme 
Cre+ mice were bred with LoxP+/+ mice to produce the F1 generation. Of these, Cre+ 
mice were saved for further use. Pups that were LoxP+/+ were used as experimental 
animals and LoxP-/- were used as controls. LoxP+/- were used for breeder pairs in order to 
continue obtaining experimental and control mice. 
2.1.3 Genotyping 
Mice were genotyped at 3 weeks old. A 1-2 mm piece at the end of their tails was 
removed and placed in a 1.5 mL microfuge tube. In each tube, 100 uL lysis buffer (50 
mM Tris, 50 mF KCL, 2.5 mM EDTA, 0.4% NP-40, 0.45% Tween-40) and 2 uL 
Proteinase K (0.4 mg/mL) were added and the tubes were placed in a 55oC water bath 
overnight. The next morning, the tubes were centrifuged for 30 seconds at 13.2 rpm and 
placed in a 95oC heat block for 10 minutes. Afterwards, 100 uL RNase DNase-free water 
was added to each tube. 
A PCR mix was assembled using 12.5 uL REDTaq ReadyMix (Sigma-Aldrich, St. Louis, 
MO, USA), 5.5 uL PCR water, 0.5 uL (0.5 mM) forward primer, and 0.5 uL (0.5 mM) 
reverse primer in each 0.2 mL PCR reaction tube. Finally, 1.5 uL mouse DNA was added 
to the tube for a total of 20.5 uL. Two sets of primers were used to genotype mice – Stat3 
and Osterix-Cre. The Stat3 primer sequences were as follows: forward – 5’-ATT GGA 
ACC TGG GAC CAA GTG G-3’ and reverse – 5’-ACATGT ACT TAC AGG GTG TGT 
GC-3’. The Osterix-Cre primer sequences were as follows: forward – 5’- CTC 
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TTC ATG AGG AGG ACC CT -3’ and reverse – 5’- GCC AGG CAG GTG CCT GGA 
CAT -3’. The tubes were placed in an Eppendorf Thermal Cycler and run for 40 cycles. 
After amplification, samples were loaded into a 2.5% agarose gel with 1x SYBR safe 
DNA stain (Life Technologies Corporation, Carlsbad, CA, USA) alongside a 100 bp 
ladder. Gels were imaged using a Typhoon FLA 9500 Scanner. 
For the Stat3 LoxP primers, a band at 520 indicated Stat3flox/flox and a band at 480 
indicated Stat3+/+. The presence of both bands indicated a heterozygous genotype. Cre 
positive mice were identified by the presence of a 615 bp band. If the mice were Cre 
negative, no band appeared. The Cre that was used is only found in pre-osteoblast cells, 
so this system ensured that Stat3 was conditionally knocked out in pre-osteoblasts. 
2.1.4 Sacrificing 
Stat3flox/flox and Stat3+/+ pups were euthanized at 8 weeks. One week prior to 
euthanization, mice were injected with calcein (green fluorochrome label, 30 mg/kg body 
weight) intraperitoneally. Two days prior to euthanization, mice were injected with 
alizarin (red fluorochrome label, 50 mg/kg body weight). Mice were sacrificed by placing 
them in a carbon dioxide chamber until all visible signs of breathing ceased for at least 
one minute. The mice were then removed from the chamber and underwent cervical 
dislocation to ensure their deaths. After sacrificing the mice, several different tissues 
were harvested including the left and right femur, left and right tibia, lumbar, and tail snip. 
The left femur was stripped of soft tissue and wrapped in 0.85% saline soaked gauze and 
stored in a -20°C freezer. The right femur was stripped of soft tissue and placed in a small 
jar filled with 10% neutral buffered formalin and placed in a 4°C refrigerator. The 
following day, the formalin was removed and replaced with 70% ethanol. The left and 
right tibia were stripped of soft tissue and placed in individual 1.5 mL microfuge tubes 
and stored in a -80°C freezer. The lumbar vertebrae was stripped of soft tissue and 
wrapped in 0.85% saline soaked gauze to be stored in a -20°C freezer. Finally, a 1-2 mm 
piece of tail was removed to confirm the genotype and prepared as previously described. 
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2.1.5 Bone Mineral Density and Content 
Bone mineral density (BMD, g/cm2) and bone mineral content (BMC, g) were measured 
in the left femurs of experimental and control mice. These femurs were thawed at room 
temperature from -20°C and placed in a peripheral dual-energy X-ray absorptiometry 
(pDXA, PIXImus II, GE-Lunar Co.) machine that calculated BMD and BMC. 
2.1.6 Micro-Computed Tomography (CT) 
Left femurs were analyzed using micro-CT. They were first thawed at room temperature 
from -20°C and wrapped in Parafilm. Femurs were stabilized with Styrofoam and placed 
in the machine (SkyScan 1176, Bruker-microCT, Kontich, Belgium). The following 
parameters were set prior to scanning: voltage: 60kV, resolution: 9 μm, binning mode: 
2K, filter: Al 0.5 mm, rotation step: 0.9°, and averaging frame: 2. 
2.1.7 Histology 
Excess tissue was trimmed off the right femurs and they were measured lengthwise. A 
pencil marked was placed around the center of the bone shaft and a bone saw was used to 
cut the bone approximately 1 millimeter distal to the pencil marking. A small portion of 
bone was shaved off the distal end. Both bone fragments were placed in small chambers 
and set in a large beaker of ethanol that was changed every 2-8 hours in gradients before 
being cleared in xylenes for 2-8 hours. Next, methyl methacrylate (MMA) and 100% 
ethanol were used to infiltrate the femurs for another 2-8 hours before being changed to 
pure MMA for another 2-8 hours. The femurs were then added to unpolymerized MMA 
and 4% dibutyl phthalate for less than a week before being embedded. 
2.1.7.1 Slide Preparation of Midshaft 
The midshaft portion of the femurs were fixed in a mixture of MMA, 4% dibutyl 
phthalate, and 0.25% Perkadox 16 inside a glass vial. After 2 hours inside of a vacuum, 
the vials were capped. These vials were set in a 4°C refrigerator overnight and allowed to 
polymerize at room temperature the following day. Vial caps were removed and a 
hammer was used to break off the glass from the polymerized samples. A wire saw was 
used to shave 4 different 40-45um cross sections off the midshaft of each femur to be 
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fixed in slides. These sections were placed onto a drop of Eukitt on a slide and pressed 
down until they made contact with the slide. A small piece of paper towel was set on top 
of the section and another slide was placed on top of the paper towel. A binder clip was 
used to hold the pieces together overnight. The next day, the top slide and paper towel 
were removed. Several drops of xylenes-thinned Eukitt (2 parts Eukitt; 1 part xylenes) 
were placed on top of the slide until the section was completely covered. These slides 
were allowed to dry overnight. The following day, sections were ground down to a 
thickness of 20-40 um by placing them section-down on water-covered 600 grit wet/dry 
silicon carbide sandpaper (LECO) and gently moved across the paper in a figure-8 
motion. After these sections were dried, the slides were dipped several times into a 
beaker of xylenes. Excess xylenes was wiped off the slide and a drop of Eukitt was 
placed on the section, followed by a glass cover slip. 
2.1.7.2 Slide Preparation of Distal 
Distal femurs were embedded in vials in a mixture of MMA, 4% dibutyl phthalate, and 
0.25% Perkadox 16. After 2 hours inside of a vacuum, the vials were capped. These vials 
were set in a 4°C refrigerator overnight and allowed to polymerize at room temperature 
the following day. A bone saw and dental model trimmer were used to trim off excess 
plastic before sections were cut. Five longitudinal sections 4 um thick were cut from each 
right femur with a tungsten-carbide knife fitted in a rotary microtome. Two of these 
sections were used to analyze fluorescent labels, one was used for TRAP staining for 
osteoclasts, one was used for VKM staining for osteoblasts, and the final section was 
used as a spare. 
2.1.8 Dynamic Histomorphometry 
Midshaft cross sections were used to calculate cortical parameters. Sections were 
analyzed at 200x under a fluorescent microscope. Periosteal and endosteal surfaces were 
traced along with single and double labels of calcein and alizarin. Using these 
measurements, MS/BS, MAR, and BFR/BS were calculated.  
Distal longitudinal sections were used to calculate trabecular parameters. Unstained 
sections were used to measure calcein and alizarin labels, as well as the bone surface. 
22 
 
Measurements were taken approximately 0.5mm proximal to the growth plate centered 
form the periosteal surface. The tissue area measured was 0.4mm2. 
2.2 Osteoclast Preparation 
2.2.1 Cell Culture 
2.2.1.1 Stat3 Suppression 
One hundred thousand RAW 264.7 cells were seeded in 5 mL antibiotic-free medium 
(1000 mL MEM-alpha in 100 mL FCS) in four different 6 cm petri dishes [2 controls 
(NC, siRNA) and 2 RANKLs (NC, siRNA)]. The plates were incubated 24 hours before 
the addition of siRNA. Stat3 Silencer Select siRNA was used to knock down Stat3 and 
New NC2 Custom Select siRNA was used as a negative control (Ambion). The siRNA 
was prepared by centrifuging the vial for 45 seconds in a mini-centrifuge. Enough water, 
in this case 250 uL was added for a final concentration of 20 uM. Two separate 1.5 mL 
RNAse-free tubes were prepared by adding 10 uL Lipofectamin RNAiMax to one and 
6.25 uL siRNA to the other. In both tubes, 500 uL OPTI-MEM was added and the tubes 
were incubated for 5 minutes in a Bio Safety Cabinet. After incubation, they were added 
together and incubated for an additional 20 minutes in a Bio Safety Cabinet. During 
incubation, the medium was removed from each of the dishes and replaced with 4 mL 
fresh antibiotic-free medium. After the second incubation, the mixture was added to 2 of 
the dishes for a final siRNA concentration of 25 nM. The plates were incubated for 6 or 
24 hours and the medium was changed with 5 mL 10% FBS 1% antibiotic medium. 
RANKL at a concentration of 10 ug/mL was added beforehand to PBS 0.1% BSA and 
stored at -20o freezer until use. After the medium was changed, 25 uL of the RANKL 
solution was added to a dish with siRNA and a dish without siRNA. The other dishes 
were given a control of 25 uL PBS 0.1% BSA. After 24 hours, the cells were harvested. 
2.2.1.2 Stat3 Overexpression 
One hundred thousand RAW 264.7 cells were seeded in 5 mL antibiotic-free medium 
(1000 mL MEM-alpha in 100 mL FCS) in four different 6 cm petri dishes [2 controls 
(NC, construct) and 2 RANKLs (NC, construct)]. The plates were incubated 24 hours 
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before the addition of the plasmid. Stat3C-Flag pRc/CMV was used to overexpress Stat3 
and was a gift from Jim Darnell (Addgene plasmid #8722). (Figure 5) An empty CMV 
plasmid was used as a negative control. Two separate 1.5 mL RNAse-free tubes were 
prepared by adding 11 uL Lipofectamine LTX to one and 6.9 uL construct (5.5 ug) or 9.2 
empty plasmid (5.5 ug) and 5.5 uL PLUS reagent to the other (Thermo Fisher Scientific). 
In both tubes, 250 uL OPTI-MEM was added and the tubes were incubated for 5 minutes 
in a Bio Safety Cabinet. After incubation, they were added together and incubated for an 
additional 20 minutes in a Bio Safety Cabinet. During incubation, the medium was 
removed from each of the dishes and replaced with 4.5 mL fresh antibiotic-free medium. 
After the second incubation, the mixture was added to 2 of the dishes. The plates were 
incubated for 6 hours and the medium was changed with 5 mL 10% FBS 1% antibiotic 
medium. RANKL at a concentration of 10 ug/mL was added beforehand to PBS 0.1% 
BSA and stored at -20o freezer until use. After the medium was changed, 25 uL of the 
RANKL solution was added to a dish with the construct and a dish the empty plasmid. 
The other dishes were given a control of 25 uL PBS 0.1% BSA. After 24 hours, the cells 
were harvested. 
2.2.2 Protein Collection 
Radioimmunoprecipitation assay (RIPA) lysis buffer was prepared in a 15 mL conical on 
ice by mixing together 500 uL RIPA, 5 uL PMSF, 5 uL Na Ortho, 17.5 uL protease 
inhibitor, and 20 uL phosphatase inhibitor per dish. The medium was aspirated from the 
dishes and the cells were washed 3x with 5 mL PBS. After the last aliquot of PBS was 
aspirated from the dishes, 500 uL RIPA buffer was added to each one. Plates were kept 
on ice for 5 minutes completely horizontally. The dishes were then scraped and the cells 
were transferred to their own 1.5 mL tube in ice. The cells were sonicated on ice for 25 
seconds per tube. These were then centrifuged at 4oC for 10 minutes on 13,200 rpm. The 
supernatant was transferred to separate tubes and placed on ice or stored in the -80o 
freezer. 
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2.2.3 Calculating Protein Concentration 
BCA was prepared in a 15 mL conical by mixing 400 uL BCA Reagent A with 8 uL 
BCA Reagent B per sample. The protein samples were microfuged and gently mixed with 
a pipetman. For each sample, 10 uL of protein was added to two different wells in a 96-
well plate. BSA protein standards in concentrations of 0, 0.125, 0.25, 0.5, 1, and 2 
mg/mL were included in the samples measured. Afterwards, 200 uL of the BCA mixture 
was added to each well sample. The plate was put in a shaker for 20 seconds and 
immediately covered in film and wrapped in aluminum foil. The plate was then incubated 
for 30 minutes in the incubator and 30 minutes at room temperature. The foil was quickly 
removed and any bubbles were popped using a pipetman before the plate was placed in 
the machine to measure the concentrations. 
2.2.4 RNA Collection 
For each sample, 500 uL RLT Plus buffer and 5 uL 2-mercaptoethanol was added in a 15 
mL conical and vortexed. The medium was aspirated from the cell culture dish and 350 
uL of the mixture was added. The cells were scraped thoroughly and transferred to a 
Qiashredder tube, which was centrifuged for 2 minutes at 13,200 rpm. The lysate was 
removed from the Qiashredder and added to the gDNA Eliminator spin column and 
centrifuged for 0.5 minutes on 10,000 rpm. After centrifugation, 350 uL 70% EtOH was 
added to the lysate, which was then transferred to an RNeasy spin column and 
centrifuged at 0.5 minutes on 10,000 rpm. The lysate was then discarded and 700 uL 
RW1 buffer was added to the tube over a filter. This was centrifuged at 0.5 minutes on 
10,000 rpm and the lysate was discarded. After, 500 uL RPE buffer was added to the tube 
over a filter and the tube was centrifuged for 0.5 minutes on 10,000 rpm. The lysate was 
again discarded and another 500 uL aliquot of RPE Buffer was added, and the tube was 
centrifuged at 2 minutes on 10,000 rpm. The lysate was discarded and the filter was 
placed over a new tube and centrifuged for 4 minutes on 13,200 rpm. The filter was then 
added to another clean tube and 100 uL RNAse-free water was poured over the filter. The 
tube was then centrifuged for 1 minute on 10,000 rpm. The filter was removed and the 
lysate was gently mixed with a pipetman. The machine was first cleaned, then blanked, 
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with RNase-free water. For each sample, 1.5 uL lysate was added to the machine and the 
RNA concentration was measured. 
2.2.5 RT-PCR 
RT-PCR mix was prepared in a 200 uL microfuge tube by adding 2 uL 10x RT buffer, 
0.8 uL 25x dNTP mix (100mM), 2 uL 10x RT random primers, and 1 uL MultiScribe 
Reverse Transcriptase per sample. The proper volume equaling 1000 ng from each RNA 
sample was added to the RT mixture. Water was added to the mixture so that the volume 
of lysate + water equaled 14.2 uL, and the total volume in the tube was 20 uL. The 
samples were then placed in the thermal cycler to make cDNA. Once the samples were 
finished, 180 uL of water was added to each tube and the contents were transferred to 1.5 
mL tubes for storage. 
2.2.6 qPCR 
qPCR mix was prepared in a 1.5 mL microfuge tube by adding 10 uL 2x Master Mix, 1 
uL forward primer, 1 uL reverse primer, 6 uL water, and 2 uL cDNA per sample. In a 96-
well plate, 2 uL of each sample (including water blank) was added to 2 different wells per 
transcript. In each well containing a sample, 18 uL of qPCR mix was added. The plate 
was then centrifuged for 1 minute on 1800 rpm. Finally, the plate was placed in a PCR-
7500 Fast system for approximately 90 minutes. This protocol was used on 40 different 
primers. (Table 1) 
2.2.7 Western Blot 
Protein samples were defrosted, centrifuged, and mixed with a pipetman before being 
placed on ice. SDS buffer was diluted 4x in each sample by adding 5 uL SDS buffer to 
1.5 mL centrifuge tubes and adding 15 uL sample to each tube. Additional tubes were 
made with 5 uL SDS buffer and 15 uL of a molecular weight standard. Once these 
mixtures were prepared, they were placed on a 100oC heat block for 5 minutes. The 
samples were then centrifuged for 1 minute on 13,200 rpm. Gel boxes were assembled 
with 10% 10 well premade gels. Loading buffer was added to the boxes and the bubbles 
were broken apart. Each of the wells was washed out with a pipetman to remove debris. 
Each of the samples was gently mixed with a pipetman, careful to avoid producing 
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bubbles. First, 10 uL of the molecular weight ladder was added to the first and last wells. 
Then, varying volumes of each protein were added to the rest of the wells, based on what 
concentrations were measured previously. The gel was run at 100 V for 10 minutes and 
150 V for 40-50 minutes, until the dye front reached the bottom of the gel. PVDF 
membranes for each gel were placed in MeOH for 10 minutes. Blotting paper, 2 for each 
membrane, was placed in a separate container which was then filled with transfer buffer 
(3.03 g Tris, 14.4 g glycine, 787 mL water, 200 mL MeOH). At the end of the 10 minutes, 
the MeOH was changed out for transfer buffer. When the gel finished running, it was 
removed from the gel box and cut carefully around the edges and in the upper left corner. 
A piece of blotting paper was placed on the transfer machine and a membrane was placed 
on top of the blotter. The gel was then carefully placed on top of the membrane and 
covered with another piece of blotting paper and pressed down with a 15 mL conical. The 
machine was turned on for varying times depending on the protein, from 30 minutes for 
smaller proteins to 55 minutes for larger proteins. Once the proteins transferred to the 
membrane, the membrane was removed and unnecessary pieces were cut away. The 
membrane was placed in blocking buffer (1 g blocking powder (non-fat dry milk), 50 mL 
PBS/Tween (1000 mL 1x PBS + 500 uL Tween 20)) and placed on a shaker at 35 
rotations per minute for 1 hour. During this time, Parafilm was placed on large plate. To 
prepare the primary antibody, 1.5 mL PBS/Tween was added to a 1.5 mL centrifuge tube 
and mixed with 1.5 uL antibody to tube. Antibodies used include the following: b-actin 
(Sigma-Aldrich), p-Stat3 (Ser727, Santa Cruz), NFATc1 (Santa Cruz), c-Fos (Santa 
Cruz), and Cathepsin K (Santa Cruz). Once the membrane finished shaking, half of the 
antibody mixture was added onto the Parafilm and the membrane was placed face down 
in the antibody. The rest of the mixture was placed on top of the membrane and allowed 
to sit for 1 hour. After this period was over, the membrane was placed in PBS/Tween and 
put on a shaker at 65 rotations per minute for 2 minutes. The PBS/Tween was changed 
and the membrane was put back on the shaker for 2, 15, 5, 5, and 5 minutes with new 
PBS/Tween each time. To make the secondary antibody, 1.5 mL PBS/Tween was added 
to a 1.5 mL centrifuge tube and mixed with 0.75 uL 2o antibody (different antibodies for 
different primaries) to tube for 2000x dilution. Half of this mixture was added to the 
Parafilm and the membrane was placed on top. The rest of mixture was added to the 
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membrane and allowed to sit for 45 minutes. After this period, the membrane was placed 
in PBS/Tween for 2 minutes. The PBS/Tween was changed and the membrane was 
placed back on the shaker for 2, 15, 5, 5, 5, and 5 minutes with new PBS/Tween each 
time. The Parafilm was changed out for a fresh piece and Saran wrap was laid flat on 
table. To prepare the developing solution, 750 uL each of Peroxide Buffer and 
Luminol/Enhancer was added to a 1.5 mL tube and shaken. Half of this mixture was 
added to the Parafilm. The membrane was placed on top and the rest of the mixture was 
added before allowing the membrane to set for 5 minutes. The membrane was dried on a 
paper towel by placing the membrane between 2 pieces and gently pressing. The 
membrane was then wrapped in the Saran wrap and placed in the LAS-3000 so pictures 
could be taken. 
2.2.8 Microarray 
Cells were prepared as previously described. Three different sets of plates were used to 
culture the following groups of cells: non-specific siRNA with no RANKL, Stat3 siRNA 
with no RANKL, non-specific siRNA with RANKL, and Stat3 siRNA with RANKL. 
RNA was collected from these triplicated groups and sent off to be analyzed. The data 
obtained was analyzed and grouped. Both RANKL groups were compared and genes 
with a significant change (p < 0.05) and with a 1.2 fold change were further analyzed 
using qPCR. All of the genes found to have differential regulation between the RANKL 
groups were entered into the Kyto Encyclopedia of Genes and Genomes (KEGG) 
pathway analysis to find possible pathways these genes are involved in. 
2.2.9 TRAP Staining 
RAW264.7 cells were seeded 1x105 cells per 5cm dish in 5ml MEM-a PS(-)FCS10%. 
Cells were transfected the following day with Stat3 siRNA 0.5nM in each dish. Exactly 
24h after transfection, cells were reseeded onto a 96-well plate.  Approximately 5000 
cells were seeded into each well and 200uL of MEM-a PS(+)FCS10% was added. After 
8h, 1 uL PBS 0.1％BSA was added to half the siRNA groups and half the control groups, 
and 1uL 10ug/mL RANKL was added to half the siRNA groups and half the control 
groups for a final concentration of 50ug/mL. These cells were incubated the following 
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day in a 37o incubator. The next day, the medium was changed again and more PBS 0.1% 
BSA and RANKL were added to their respective wells. At 72-96h, the cells were 
observed for floating. Before they dissociated, they were stained with TRAP. 
2.3 Statistical Analysis 
All data are reported as mean ± standard error of the mean. Groups were compared to test 
for significance using a 2 sample t-test with Excel function =TTEST(array1,array2,2,2). 
Significance was assumed if p < 0.05 and high significance was assumed if p < 0.01. 
Significant outliers were removed from the sample using Grubbs’ test through the 
GraphPad calculator. 
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 RESULTS CHAPTER 3.
3.1 OSX-Cre Stat3-LoxP cKO 8-Week Mouse Models 
3.1.1 Phenotypes 
Using the Osterix-Cre Stat3-LoxP breeding scheme, 7 male WT, 4 male KO, 8 female 
WT, and 9 female KO mice were generated. There was a 32.41% highly significant 
decrease in weight between the WT and KO males (p < 0.01) as well as a 19.68% highly 
significant decrease in weight between the WT and KO females (p < 0.01). The average 
body weights for each mouse type with standard deviation are as follows: WT male 19.16 
± 2.25g, cKO male 12.95 ± 3.01g, WT female 16.06 ± 1.68g, cKO female 12.9 ± 2.35g. 
(Figure 6) These weights were reflected in the notable size difference between the WT 
and cKO mice as well. (Figure 7) 
There was a highly significant decrease in femur length from WT males to cKO males (p 
< 0.05) as well as from WT females to cKO females (p < 0.01). (Figure 8) The average 
femur length for WT males was 14.0 ± 0.4 mm and the average femur length for cKO 
males was 11.4 ± 0.8 mm, which resulted in an 18.4% decrease. The average femur 
length for WT females was 13.4 ± 0.9 mm and the average femur length for cKO females 
was 12 ± 1 mm, which resulted in a 13.3% decrease. (Figure 9) 
Measurements of bone mineral density revealed a slight decrease from the WT males to 
the cKO males that did not reach significance. The BMD also decreased from WT 
females to cKO females reaching signifance (p < 0.05). WT males had a BMD of 0.040 ± 
0.003 g/cm2 while cKO males had a BMD of 0.032 ± 0.007 g/cm2 resulting in an 18.3% 
decrease. WT females had a BMD of 0.038 ± 0.003 g/cm2 while cKO females had a 
BMD of 0.034 ± 0.005 g/cm2 resulting in an 11.1% decrease. (Figure 10) 
Measurement of bone mineral content (BMC) revealed a significant decrease from the 
WT males to the cKO males (p < 0.05). There was also a significant decrease from the 
WT females to the cKO females (p < 0.05). WT males had a BMC of 0.014 ± 0.003 g 
while the cKO males had a BMC of 0.008 ± 0.005 g, resulting in a 45.1% decrease. WT 
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females had a BMC of 0.012 ± 0.003 g while the cKO females had a BMC of 0.008 ± 
0.004 g resulting in a 33.8% decrease. (Figure 11) 
3.1.2 Micro-CT Analysis 
Micro CT analysis revealed a metaphyseal defect that appeared in cKO males and 
females in relation to their WT counterparts. These femurs appeared shorter with a 
bulging out at the metaphysis. (Figure 12) 
In the micro CT analysis of the distal region of the femur of trabecular bone, no 
significant differences were observed in any of the parameters that were measured, which 
included tissue volume, bone volume, bone volume over tissue volume, tissue surface, 
bone surface, bone surface over bone volume, and bone surface over tissue volume. Bone 
surface over bone volume exhibited somewhat of a decrease between WT and cKO males, 
but did not fully reach significance. 
In the micro-CT analysis of cortical bone in the midshaft region of 8-week experimental 
mice, both the male and female mice showed a significant decrease from the WT to the 
cKO in tissue volume. (Figure 13)  The male decrease was highly significant going from 
12 ± 2 mm3 in the WT to 7 ± 2 mm3 in the cKO. The female significant decrease was 11 
± 2 mm3 in the WT to 8 ± 3 mm3 in the cKO. There was a similar pattern in bone volume 
where WT males had 10 ± 2 mm3 and cKO males had 6 ± 2 mm3, giving a highly 
significant decrease. WT females had 9 ± 2 mm3 where cKO females had 7 ± 2 mm3, 
giving a significant decrease in bone volume. (Figure 14) There was, however, no 
significant change seen in percentage of bone volume over tissue volume from WT to 
cKO in either the males or the females. (Figure 15) No significant change was seen in 
these groups for tissue surface either. There was a slight decrease from WT males to cKO 
males and a slight increase from WT females to cKO females, but neither reached 
significance. (Figure 16) cKO males showed a significant decrease in bone surface area 
compared to the WT males while there was no change in females. WT males had a bone 
surface area of 350 ± 60 mm2 compared to the cKO that had a bone surface area of 260 ± 
60 mm2. The same pattern was seen in bone surface perimeter where WT males had bone 
surface perimeter of 240 ± 40 mm and cKO males had a bone surface perimeter of 180 ± 
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40 mm, giving a significant decrease. (Figure 17) Bone surface over bone volume was 
highly significantly increased from the WT males to the cKO males as well as from the 
WT females to the cKO females. WT males had a BS/BV of 34 ± 4 mm-1 while cKO 
males had a BS/BV of 48 ±4 mm-1. (Figure 18) WT females had a BS/BV of 33 ± 4 mm-1 
while cKO females had a BS/BV of 47 ± 9 mm-1. 
3.1.3 Dynamic Histomorphometry Measurements 
In the measurement of the calcein and alizarin labels of the trabecular distal region of the 
femur, a significant increase in MS/BS was seen in female cKO mice compared to the 
control. (Figure 19) cKO females had 49 ± 2% MS/BS while WT females had 40 ± 3%. 
There was no significant difference in males for this parameter. Both the MAR and 
BFR/BS rates yielded no significant differences in either the males or the females. 
In measuring the labels in the cortical midshaft region, no significant differences were 
seen in the males. On the endocortical surface, there was a significant decrease in cKO 
females regarding MS/BS, MAR, and BFR/BS. (Figure 20) WT females had an MS/BS 
of 88 ± 3%, an MAR of 0.8 ± 0.1 um/day, and a BFR/BS of 250 ± 40 um3/um2/year, 
while cKO females had an MS/BS of 74 ± 4%, an MAR of 0.48 ± 0.5 um/day, and a 
BFR/BS of 130 ± 20 um3/um2/year. On the periosteal surface, there was a significant 
increase in cKO females regarding MAR and BFR/BS, but no significant difference in 
MS/BS. (Figure 21) 
3.2 Osteoclast Stat3 siRNA and Overexpression 
3.2.1 Microarray Analysis 
The microarray performed on the four different groups of RAW 264.7 cells with 24 hour 
RANKL stimulation in triplicate revealed 296 genes that were significantly changed 
when Stat3 was knocked down compared to controls in RANKL. (Figure 22) Of these, 
192 were significantly upregulated and 104 were significantly downregulated when Stat3 
was knocked down in the RANKL groups compared to the control (p < 0.05). Of these, 
41 genes were brought to light which in addition to having a p value less than 0.05 also 
had at least a 1.2 fold change between the two RANKL groups. Several of these genes 
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did not have information in the NCBI database and could not be further tested. However, 
26 of the genes were analyzed for further confirmation using qPCR. Kyto Encyclopedia 
of Genes and Genomes (KEGG) pathway analysis of the microarray data revealed several 
cellular pathways these genes are involved in. (Table 2) Pathways that were of 
significance included Rheumatoid arthritis, Lysosome, Regulation of actin cytoskeleton, 
Collecting duct acid secretion, Amoebiasis, Phagosome, and Cell adhesion molecules 
(CAMs) (p < 0.05). 
3.2.2 mRNA Expression Patterns 
In the qPCR analysis of siRNA Stat3 knockdown samples stimulated with RANKL for 
24h, Stat3 was shown to be sufficiently knocked down compared to controls. (Figure 23) 
Atp6v0d2, Bcar3, Cathepsin K, DEL1, DMPK, EEIG1, Hyal1, Ifi202b, Mapk11, Nfkbie, 
Nhedc2, OSCAR, Pdgfb, Rorc, Serpinb6b, Src, and 5-HTT qPCR confirmed the 
upregulation pattern seen in the microarray when Stat3 was knocked down with RANKL 
induction. (Figure 24) CD97, CEBPA, Gadd45g, HOX-a1, and Sla qPCR confirmed the 
downregulation pattern seen in the microarray when Stat3 was knocked down with 
RANKL induction. (Figure 25) COX1, Icam2, NOX2, and S1pr1 did not confirm 
microarray results, but none of their values reached significance. Out of 11 genes (Akt, 
AMPK, c-Fos, DC-STAMP, GLUT1, Mitf, NFATc1, PPARg, PU.1, TRAP, and UCP2) 
analyzed that were not found in the microarray results, only c-Fos was found to have a 
significant decrease in mRNA expression when Stat3 was knocked down. 
3.2.3 Protein Production Patterns 
3.2.3.1 Stat3 siRNA Knockdown 
In the western blot analyses performed using the Stat3 siRNA, the b-actin control showed 
an even distribution of protein amounts. (Figure 26) p-Stat3 levels decreased in response 
to the siRNA in 6h and 24h of RANKL induction. (Figure 27) NFATc1 levels increased 
significantly at 6h and only slightly at 24h when Stat3 was knocked down compared to 
the control. (Figure 28) c-Fos levels slightly decreased at 6h and 24h in RANKL when 
Stat3 was knocked down, but this decrease was not significant. (Figure 29) Cathepsin K 
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levels increased significantly at 24h hours in RANKL when Stat3 was knocked down 
compared to the control group. (Figure 30) 
3.2.3.2 Stat3 Overexpression Construct 
In the western blot analyses performed using the Stat3 overexpression construct, the b-
actin control showed an even distribution of protein amounts. (Figure 31) p-Stat3 levels 
increased significantly in response to the overexpression construct in each of these 
samples. (Figure 32) NFATc1 levels remained the same when Stat3 was overexpressed 
compared to the control. (Figure 33) c-Fos levels increased slightly though insignificantly 
at 6h in RANKL when Stat3 was overexpressed. (Figure 34) 
3.2.4 TRAP Staining 
In the TRAP staining done on RAW 264.7 cells stimulated with RANKL for 3-4 days, 
the number of multi-nucleated osteoclasts significantly increased when Stat3 siRNA was 
used compared to the negative control. (Figure 35 & Figure 36) 
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 DISCUSSION CHAPTER 4.
4.1 Osterix Cre Stat3 KO in Osteoblasts 
Both the male and female cKO mice exhibited a highly significant decrease in body 
weight as well as femur length in relation to their WT counterparts. cKO females had a 
significant decrease in bone mineral density compared to WT females. The same pattern 
was seen in males, but did not reach significance. Both male and female cKO mice had a 
significant decrease in bone mineral content compared to their WT counterparts as well. 
cKO mice also tended to be much smaller than the WT mice. There were very clear 
differences between WT and cKO mice phenotypically. Overall, there does not seem to 
be a large difference between the sexes in how Stat3 affects their pre-osteoblasts. Both 
the weight and femur length did seem to have a larger difference between the male WT 
and cKO than the female WT and cKO. It also seemed easier to breed female cKO than 
male cKO as there were more than twice as many female cKO obtained than male cKO. 
This could indicate that survival in the womb might have been more heavily affected in 
male cKO than in female cKO. Aside from experimental animal numbers, there is no 
further evidence of this effect based on the present study.  
Micro-CT analysis of the 8-week mouse femurs revealed a metaphyseal defect in cKO 
mice of both sexes that appeared as a bulge in the metaphysis that was not present in WT 
mice. No difference between WT and cKO mice was observed in the trabecular analysis. 
Cortical bone analysis revealed several differences between WT and cKO mice. In male 
mice, a significant decrease was seen in tissue volume, bone volume, bone surface area, 
and bone surface perimeter from the WT to the cKO, and a significant increase was seen 
in bone surface over bone volume from the WT to the cKO. In female mice, a significant 
decrease was seen only in tissue volume and bone volume from the WT to the cKO, 
while a significant increase was seen in bone surface over bone volume from the WT to 
the cKO. No significant differences were observed in the percentage of bone volume over 
tissue volume, tissue surface area, or tissue surface perimeter in either sexes. Again, there 
seems to be a small difference between the sexes in that males seem to be slightly more 
affected by the Stat3 knockout in pre-osteoblasts than the females. 
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In the dynamic histomorphometry analyses, no significant differences were seen in the 
males, but several differences were observed in the females. In the trabecular region, 
cKO females had higher active osteoblast numbers as indicated by a higher MS/BS 
percentage. In the endocortical region, cKO females had significantly lower active 
osteoblast numbers, osteoblast activity, and bone formation rate as indicated by MS/BS, 
MAR, and BFR/BS, respectively. On the periosteal surface, cKO females actually had 
higher osteoblast activity and higher bone formation rate compared to WT controls. In 
females, there seems to be a substantial impairment of osteoblast function on the 
endocortical surface but not the periosteal surface. There is in fact an increase in function 
and bone formation rate on the periosteal surface of cKO females. The increase of 
activity on the periosteal surface could possibly exist in order to counteract the lack of 
activity on the endocortical surface. However, there is currently no other evidence of this 
provided by the current study. 
Overall, there is a clear effect on skeletal development by Stat3 on osteoblasts. When 
Stat3 was conditionally knocked out in osteoblasts of developing mice, several different 
parameters were affected that led to a negative effect on bone development. Without 
Stat3, osteoblasts were unable to properly perform their jobs causing a decrease in size, 
femur length, and bone volume. This indicates that Stat3 is necessary for osteoblast 
differentiation and/or function. Because there is communication between osteoblasts and 
osteoclasts, the lack of Stat3 in osteoblasts could also have an indirect effect on 
osteoclasts. Osteoblasts are able to inhibit osteoclast activity through secretion of RANK 
decoy receptor OPG, so an impairment in osteoblast function by Stat3 could lead to a 
decrease in secretion of this receptor thus increasing osteoclast activity. 
A study by Itoh et al. used a similar model that we used by incorporating an α1(I)-
collagen Cre-LoxP to conditionally knock out Stat3 in osteoblasts. Mice lacking Stat3 in 
their osteoblasts had osteoporotic phenotypes, indicating their osteoblast function was 
impaired because of the lack of Stat3 (Itoh et al.). This was similar to our findings that 
osteoblasts need Stat3 in order for their osteoblasts to properly differentiate and function. 
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A study by Nicolaidou et al. also found similar results using an in vitro study where Stat3 
was either overexpressed or knocked down in osteoblasts. They were able to demonstrate 
the necessity of Stat3 in differentiating osteoblasts from MSCs. While this study did not 
reveal any information on how function was affected, the study did confirm that Stat3 is 
important in osteoblast differentiation. 
These studies did not provide any evidence of sex-based differences, but they did concur 
with our study that Stat3 is needed to differentiate osteoblasts and aid in their function. 
Our study did nonetheless highlight a probable sex-based difference which could be 
explored further in future studies. 
4.2 Osteoclast in vitro Analysis 
The microarray analysis paired with confirmatory results from the qPCR tests revealed a 
vast difference in gene expression between cells with normal levels of Stat3 in relation to 
the Stat3 knockdown cells when stimulated with RANKL for 24 hours. Several of the 
genes analyzed in the microarray and qPCR that significantly increased in response to 
Stat3 siRNA knockdown are known to be important – if not necessary – for 
osteoclastogenesis or osteoclast function such as Atp6v0d2, Cathepsin K, EEIG1 (aka 
FAM102A), and Src. This indicates that Stat3 is necessary for downregulating the 
transcriptional activity of factors needed in osteoclastogenesis. Because of this, Stat3 
seems to have a negative effect on osteoclastogenesis, as well as osteoclast function. 
In the western blot analyses, production of NFATc1 and Cathepsin K increased in 
response to Stat3 siRNA knockdown under RANKL stimulation. c-Fos production 
decreased slightly, though did not reach significance, in response to Stat3 siRNA 
knockdown. The upregulation or downregulation was partly dependent on the amount of 
time the cells were stimulated with RANKL. NFATc1 only appeared to be affected at 6 
hours of stimulation with little effect at 24 hours. 
When Stat3 was overexpressed, c-Fos increased somewhat but not significantly in 
samples with the Stat3 construct compared to samples with an empty plasmid. Based on 
the western blot for Stat3 knockdown in c-Fos, this result was expected. NFATc1 
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production exhibited no change at 6h between the RANKL control and overexpression 
groups. This is not the result that was expected based on the Stat3 knockdown western 
blots where NFATc1 increased when Stat3 was knocked down. 
Taking all of the western blot experiments into account, Stat3 seems to have a somewhat 
positive role on c-Fos expression and production, a negative role on NFATc1 production, 
and a negative role in Cathepsin K production. Since c-Fos is known to upregulate 
NFATc1, this finding is curious. If Stat3 has no effect on, or even upregulates, c-Fos, 
seeing a similar effect on NFATc1 – and in turn, Cathepsin K – would be expected. 
However, this is not the case. Based on the negative effect Stat3 seems to have on 
NFATc1 and Cathepsin K, Stat3 appears to have a negative role in osteoclastogenesis and 
osteoclast function, as was also indicated by the microarray and qPCR analysis. The 
slight positive role Stat3 has on c-Fos is peculiar though and should be explored further. 
TRAP staining revealed an increase in multi-nucleated osteoclast numbers when Stat3 
was knocked down compared to the controls. This indicates that Stat3 could be 
suppressing osteoclast fusion and/or differentiation into multi-nucleated cells. The 
microarray and qPCR analyses revealed the inhibitory role Stat3 has on Atp6v0d2, which 
is important in osteoclast fusion. Therefore, the idea that Stat3 could be preventing fusion 
is entirely plausible. The microarray, qPCR, and western blot analyses all revealed 
several genes important for differentiation that Stat3 suppressed, such as NFATc1, so the 
TRAP stain could have simply revealed more evidence of the role Stat3 has in 
downregulating osteoclastogenesis. 
Zhang et al. also studied the effect of Stat3 on osteoclasts in vivo and in vitro by 
conditionally knocking out Stat3 in hematopoietic stem cells (HSCs) of 3-4 week old 
mice using Tie2-Cre. When they conditionally knocked out Stat3 in osteoclasts, they 
believed there was an increase in osteoclast number that led to osteoporotic phenotypes 
(Z. Zhang et al.). Upon culturing these cells in vitro for further testing they found that c-
Fos expression and production greatly increase in the absence of Stat3 (Z. Zhang et al.). 
Zhang et. al believed that Stat3 is a negative regulator of osteoclastogenesis due to its 
apparent inhibitory effect on c-Fos, which is needed for osteoclast differentiation (Z. 
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Zhang et al.). While our findings agree with this study in that Stat3 is a negative regulator 
of osteoclastogenesis, they disagree with this study in that we demonstrated that c-Fos 
levels increase when Stat3 levels increase, and c-Fos levels decrease when Stat3 is 
suppressed. While Stat3 has a negative role in many different important factors in 
osteoclastogenesis, it has an overall positive effect on c-Fos. Main differences in our 
studies are that we knocked down or overexpressed Stat3 while Zhang et. al conditionally 
knocked out Stat3. Additionally, this conditional knockout was not osteoclast-specific, 
rather it was for HSCs which differentiate into many different cell types. This could 
indicate that Stat3 acts as a switch for c-Fos that is stage-dependent. Before there is any 
commitment to the osteoclast lineage, Stat3 could be a negative regulator of c-Fos. Once 
cells have committed to the lineage, Stat3 could then act as a positive regulator of c-Fos. 
Li et. al performed a study similar to ours by culturing murine osteoclast precursor 
RAW264.7 cells with M-CSF, RANKL, and varying concentrations of JAK inhibitor 
AG490. They found that the addition of AG490 inhibited osteoclast formation, leading 
them to believe that Stat3 must be a positive regulator of osteoclastogenesis (Li et al.). 
While this conclusion is relatively reasonable, one cannot definitively say whether Stat3 
is a main factor in this regulation of osteoclastogenesis due to the wide array of cellular 
pathways JAK influences that do not directly involve Stat3. While these findings seem to 
contradict ours, the study we performed directly affected Stat3 while the study by Li et al. 
indirectly affected it. The effects they saw on osteoclastogenesis could be due to other 
factors affected by the JAK pathway that overpowered the effect on Stat3. 
4.3 Future Directions 
The osteoblast study revealed an overall positive effect of Stat3 on osteoblast 
differentiation. Osterix is important for osteoblast differentiation, and knocking Stat3 out 
at this stage had several major effects on bone development. Future studies could include 
knocking out Stat3 in different stages to elucidate its role on osteoblast function or other 
areas of osteoblast development more clearly. An in vitro study could also be useful in 
determining specifically what factors Stat3 is affecting within the cell that prevents 
proper differentiation. Further investigation could also be done on the potential sex 
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differences that occurred between the male and female mice. Males seemed to be more 
affected by the loss of Stat3 in pre-osteoblasts, so there could be factors in the female 
mice protecting them from equally damaging effect such as estrogen, which is thought to 
inhibit osteoclast differentiation (Kameda, Mano and Yuasa). Lower levels of bone 
resorption could help to offset the effect of less bone formation. Isolating osteoclasts 
from the WT and cKO mice to observe differences in function could be a useful next step 
to understand the potential sex difference seen in these mice. Another reason for this sex 
difference could be the relatively low number of animals used in the study. The cKO 
males were especially difficult to obtain, and only half the number of cKO males were 
available for the study compared to the other groups. In the future, a larger sample of 
animals should be obtained in order to increase the certainty of significance in these 
results. 
The osteoclast study uncovered that Stat3 has more of a negative role in osteoclasts based 
on its effects on fusion, differentiation, and function. Because of this discovery, 
observing the role of Stat3 at each of these stages more carefully could be beneficial. The 
main factor observed in this study was differentiation, but observing the effect Stat3 has 
on osteoclast function could also be insightful. A useful experiment to find this 
information would be a bone resorption assay which could measure the activity of 
osteoclasts with normal levels of Stat3 and the activity of osteoclasts with higher or lower 
levels of Stat3 to see if osteoclast function is helped or hindered by a difference in Stat3 
levels. 
Another factor to examine in the osteoclast study is using further time points. This study 
observed the effect Stat3 has in earlier stages of osteoclastogenesis (3-24 hours), but 
further signaling events could be occurring later on. Samples could be collected at 48, 72, 
or even 96 hours to elucidate the role of Stat3 in later differentiation stages. 
While this study revealed a negative effect Stat3 has on osteoclastogenesis, the pathways 
with which Stat3 exhibits this effect are still unclear. Further studies using qPCR and/or 
western blot analyses could be used on different genes known to be relevant for 
osteoclastogenesis to further explicate the pathways to which Stat3 affects 
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osteoclastogenesis. A good starting point might be TRAF6 since this is the earliest 
protein in the RANKL signaling cascade and is known to interact with Stat3 in other cells 
types (Wei, Yuan and Jin). 
Along the same lines of looking more closely at the pathways Stat3 affects in 
osteoclastogenesis, a study could be done to find whether the proteins in this study are 
affected directly or indirectly by Stat3. It is already known that STAT proteins can bind 
the promoter region for c-Fos, causing a direct effect in its upregulation. It could be 
useful to find whether the same is true for NFATc1 and Cathepsin K or if Stat3 is causing 
an indirect effect by upregulating or downregulating other factors that induce these genes.  
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Table 2: KEGG pathway analysis based on microarray data  
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FIGURES 
 
 
 
 
Figure 1: Intracellular pathway of osteoclast being induced by RANKL (Okamoto and 
Takayanagi) 
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Figure 2: Osteoblast differentiation pathway (Arboleya and Castañeda) 
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Figure 3: Stat3 signaling pathways (Yu et al.) 
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Figure 4: Stat3 structure with listed mutations (Holland et al.) 
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Figure 5: Stat3-C Flag pRc/CMV 7969 bp overexpression construct (Bromberg et al.).  
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Figure 6: Body weights of experimental mice at 8 weeks of age. Highly significant 
decrease in weight observed between WT males and cKO males as well as WT females 
and cKO females.  
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Figure 7: Female WT (left) and female cKO (right) at 7 weeks 
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Figure 8: Dissected femurs of male (left) and female (right) 8-week mice. In both images, 
the femur to the left is WT and the femur to the right is cKO. Both sexes exhibited a 
highly significant decrease in length in cKO in comparison to their WT counterparts.  
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Figure 9: Femur lengths of experimental mice at 8 weeks of age. Highly significant 
decrease in femur length observed between WT males and cKO males as well as WT 
females and cKO females. 
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Figure 10: Bone mineral density of experimental mice at 8 weeks of age. No significant 
difference between WT males and cKO males. Significant decrease in BMD observed 
between WT females and cKO females. 
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Figure 11: Bone mineral content of experimental mice at 8 weeks of age. Significant 
decrease observed between WT males and cKO males as well as WT females and cKO 
females. 
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Figure 12: Micro CT analysis of 8-week mouse femurs. From left to right: WT males (A), 
cKO males (B), WT females (C), and cKO females (D). cKO mice of both sexes had 
shorter femurs that had a metaphyseal defect indicated by the arrow.  
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Figure 13: Total volume of cortical region based on Micro-CT analysis in experimental 
mice at 8 weeks of age. Highly significant decrease observed between male WT and cKO 
mice. Significant decrease observed between female WT and cKO mice. 
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Figure 14: Bone volume of cortical region based on Micro-CT analysis in experimental 
mice at 8 weeks of age. Highly significant decrease observed between male WT and cKO 
mice. Significant decrease observed between female WT and cKO mice. 
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Figure 15: Bone volume over tissue volume of cortical region based on Micro-CT 
analysis in experimental mice at 8 weeks of age. No significant changes were seen 
between WT or cKO in either the males or the females. 
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Figure 16: Total surface area and perimeter of cortical region based on Micro-CT 
analysis in experimental mice at 8 weeks of age. No significant changes were seen 
between WT or cKO in either the males or the females. 
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Figure 17: Bone surface area and perimeter of cortical region based on Micro-CT 
analysis in experimental mice at 8 weeks of age. A significant decrease was seen from the 
WT to the cKO males in both categories. No significant change was seen in females. 
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Figure 18: Bone surface over bone volume of cortical region based on Micro-CT analysis 
in experimental mice at 8 weeks of age. A highly significant increase was seen from the 
WT to the cKO in both males and females. 
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Figure 19: Dynamic histomorphometry of trabecular region showing mineralizing surface 
over bone surface. A significant increase was seen in cKO females compared to WT 
females. No significant difference was seen in males. 
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Figure 20: Endocortical surface parameters showing significant decrease in cKO females 
for mineralizing surface over bone surface, mineral apposition rate, and bone formation 
rate over bone surface. No significant difference was seen in males. 
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Figure 21: Periosteal surface parameters showing significant increase in cKO females for 
mineral apposition rate and bone formation rate over bone surface. No significant 
difference was seen for either sexes in mineralizing surface over bone surface. No 
significant change was seen in males.  
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Figure 22: Microarray heat map of 24 hour RANKL samples. 
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Figure 23: qPCR analysis of Stat3 primer showing highly significant knockdown 
compared to non-specific controls. 
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Figure 24: qPCR analysis of genes upregulated in Stat3 siRNA 24 hour RANKL groups. 
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Figure 25: qPCR analysis of genes downregulated in Stat3 siRNA 24 hour RANKL 
groups.  
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Figure 26: Western blot b-actin bands of Stat3 siRNA knockdown samples quantified 
with relative density at 6 hours (A) and 24 hours (B). Each band from left to right 
represents pre-osteoclast control, pre-osteoclast with Stat3 siRNA, RANKL-stimulated 
osteoclast control, and RANKL-stimulated with Stat3 siRNA. 
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Figure 27: Western blot p-Stat3 bands of Stat3 siRNA knockdown samples quantified 
with adjusted density to b-actin at 6 hours (A) and 24 hours (B). Each band from left to 
right represents pre-osteoclast control, pre-osteoclast with Stat3 siRNA, RANKL-
stimulated osteoclast control, and RANKL-stimulated with Stat3 siRNA. 
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Figure 28: Western blot NFATc1 bands of Stat3 siRNA knockdown samples quantified 
with adjusted density to b-actin at 6 hours (A) and 24 hours (B). Each band from left to 
right represents pre-osteoclast control, pre-osteoclast with Stat3 siRNA, RANKL-
stimulated osteoclast control, and RANKL-stimulated with Stat3 siRNA. 
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Figure 29: Western blot c-Fos bands of Stat3 siRNA knockdown samples quantified with 
adjusted density to b-actin at 6 hours (A) and 24 hours (B). Each band from left to right 
represents pre-osteoclast control, pre-osteoclast with Stat3 siRNA, RANKL-stimulated 
osteoclast control, and RANKL-stimulated with Stat3 siRNA. 
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Figure 30: Western blot Cathepsin K bands of Stat3 siRNA knockdown samples 
quantified with adjusted density to b-actin at 24 hours (A). Each band from left to right 
represents pre-osteoclast control, pre-osteoclast with Stat3 siRNA, RANKL-stimulated 
osteoclast control, and RANKL-stimulated with Stat3 siRNA. 
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Figure 31: Western blot b-actin bands of Stat3 overexpression construct samples 
quantified with relative density at 6 hours (A). Each band from left to right represents 
pre-osteoclast control, pre-osteoclast with Stat3 construct, RANKL-stimulated osteoclast 
control, and RANKL-stimulated with Stat3 construct. 
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Figure 32: Western blot p-Stat3 bands of Stat3 overexpression construct samples 
quantified with relative density at 6 hours (A). This graph illustrates the significant 
increase in Stat3 production for both overexpression groups. 
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Figure 33: Western blot NFATc1 bands of Stat3 overexpression construct samples 
quantified with relative density at 6 hours (A). This graph illustrates there is no 
significant difference between the RANKL groups when Stat3 is overexpressed. 
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Figure 34: Western blot c-Fos bands of Stat3 overexpression construct samples quantified 
with relative density at 6 hours (A). This graph demonstrates a slight but insignificant 
increase in c-Fos production when Stat3 is overexpressed. 
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Figure 35: TRAP-stained RAW 264.7 cells stimulated with RANKL. A significant 
increase in multi-nucleated osteoclasts was observed when Stat3 was knocked down. 
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Figure 36: TRAP-stained RAW 264.7 cells. From left to right, top to bottom: non-
specific siRNA without RANKL (A), Stat3 siRNA without RANKL (B), non-specific 
siRNA with RANKL (C,E), and Stat3 siRNA with RANKL (D,F). 
